Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7299
    +0.0002 (+0.02%)
     

  • CRUDE OIL

    82.75
    -0.06 (-0.07%)
     

  • Bitcoin CAD

    88,504.59
    -3,026.47 (-3.31%)
     

  • CMC Crypto 200

    1,394.20
    -29.90 (-2.10%)
     

  • GOLD FUTURES

    2,331.10
    -7.30 (-0.31%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,489.75
    -174.75 (-0.99%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,977.16
    -482.92 (-1.26%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Can Carl Icahn Save Bristol Myers Squibb?

Joseph Lu
Updated

Bristol-Myers Squibb Company BMY experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

Bristol-Myers, a global leader in biopharmaceutical, hasn’t been able to convince shareholders that its product can compete against rivals like Merck & Co MRK. A product that the company pioneered is cancer immunotherapy, which aims to fight the diseases using the body’s immune system.

The company took a hit in January when they announced that their lung-cancer treatment wouldn’t get approval as fast as hoped. Investors feared the delay would put Bristol-Myers behind its competitors.

On Tuesday, the company announced that it would add three directors to its board, making it a total of 14 seats, and buy back $2 billion in stock in a pact with another activist, Jana Partners LLC. Current Chairman Lamberto Andreotti will also retire, as it was announced back in December.

ADVERTISEMENT

The Wall Street Journal reported that Icahn, who has a successful history in pushing for deals among pharmaceutical companies, owns a large stake and believe the company has a good potential to become an “attractive takeover.”

Bristol-Myers is a Zacks Rank #3 (Hold). The company’s stock rose slightly right after Icahn’s interest was reported at 4 p.m. in New York.

 
Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?

Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
 
Merck & Company, Inc. (MRK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research